相关实验视频

Updated: Sep 9, 2025

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

针对KDM5C脱甲基酶活性的选择性抑制剂的设计

Valentina Lukinović¹, Hemanta Adhikary², Matthew Hoekstra²

¹Institute of Biochemistry, Carleton University, Ottawa, ON K1S 5B6, Canada; NuvoBio Corporation, Ottawa, ON K1M 2J2, Canada.

Structure (London, England : 1993)

|August 28, 2025

概括

研究人员开发了一种针对KDM5C脱甲基酶活性的新型抑制剂,在体内显著减少结肠癌瘤的生长. 这一发现为向癌症治疗提供了有前途的新途径.

科学领域:

生物化学
分子生物学
癌症学

背景情况:

包括蛋白质氨酸脱甲基化在内的翻译后修饰对于细胞过程至关重要.
lysine 脱甲基化的失调与人类病理,特别是癌症有关.
KDM5酶家族,特别是KDM5C,通过去除甲基标记,在基因转录中发挥关键作用,并与癌症生物学和药物耐药性有关.

研究的目的:

设计和描述一种针对KDM5C脱甲基酶活性的新型抑制剂.
评估抑制剂对其他KDM家族成员的选择性.
评估KDM5C抑制剂在减少瘤生长中的有效性.

主要方法:

对KDM5C特有的抑制剂的设计和合成.
生物化学测试以确定抑制剂的选择性.
使用瘤模型进行体内研究以评估治疗潜力.

主要成果:

成功设计了一种具有高选择性的新型抑制剂.
该抑制剂在体内显著降低了瘤生长.
这些发现表明KDM5C抑制是治疗结肠癌的可行策略.

结论:

用抑制剂向KDM5C是一种有前途的结肠癌治疗策略.
抑制剂具有改变癌症治疗模式的潜在向疗法.
进一步开发KDM5C抑制剂可能会导致新的癌症治疗方法.

关键词:

RNF20甲基化基因组 H3K4me3 氨酸脱甲基化基阵列类抑制剂翻译后的修改治疗药物异种移植模型

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...